Do you want to read an article? Please log in or register.
RUBY: Dostarlimab plus carboplatin and paclitaxel shows no detrimental effect on QoL in patients with primary advanced or recurrent endometrial cancer
Gynecologic Cancer
CHICAGO 2025
Related content
Gynecologic Cancer
Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial
Ann Oncol
Powell MA, Bjørge L, Willmott L, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Gropp-Meier M, Stuckey A, Boere I, Gold MA, Segev Y, Gill SE, Gennigens C, Sebastianelli A, Shahin MS, Pothuri B, Monk BJ, Buscema J, Coleman RL, Slomovitz BM, Ring KL, Herzog TJ, Balas MM, Grimshaw M, Stevens S, Lai DW, McCourt C, Mirza MR
doi: 10.1016/j.annonc.2024.05.546
ESMO 2024
Breast Cancer
ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria
Gastrointestinal Cancer
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol
Randon G, Lonardi S, Fassan M, Palermo F, Tamberi S, Giommoni E, Ceccon C, Di Donato S, Fornaro L, Brunetti O, De Vita F, Bittoni A, Chini C, Spallanzani A, Nappo F, Bethaz V, Strippoli A, Latiano T, Cardellino GG, Giuliani F, Morano F, Niger M, Raimondi A, Prisciandaro M, Pircher CC, Sciortino C, Marchesi S, Garattini SK, Airò G, Miceli R, Di Bartolomeo M, Pietrantonio F
doi: 10.1016/S1470-2045(24)00580-1
Gynecologic Cancer
Oncologic outcome of metachronous oligometastatic recurrence in advanced cervical cancer patients after primary radio-chemotherapy
J Gynecol Oncol
Bartl T, Dorittke T, Ciocsirescu C, Knoth J, Schmid M, Grimm C, Sturdza A
doi: 10.3802/jgo.2025.36.e99
Breast Cancer
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials
Eur J Cancer
Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, Freyer G, Decker T, Kalinsky K, Sopher G, Gao M, Hu H, Kuemmel S
doi: 10.1016/j.ejca.2025.115225
SABCS 2024
Breast Cancer
Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291
RECOMMENDED
Gynecologic Cancer
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 1
Recommended by
Dr Andreas Müller, Faculty Member
Lancet Oncol
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP, AtTEnd study group
doi: 10.1016/S1470-2045(24)00334-6
ESMO 2024
Gynecologic Cancer
KEYNOTE-A18: Pembrolizumab plus chemoradiotherapy improves PFS and OS in patients with high-risk, locally advanced cervical cancer
Genitourinary Cancer